




<rss xmlns:a10="http://www.w3.org/2005/Atom" version="2.0">
    <channel>
        <title>Acute Heart Failure</title>
        <link>http://www.acc.org/Feed?clinicalTopicID=729dd08e-0a1b-4aa5-bd2a-5e3f31006cb0</link>
        <description>Clinical Topic Feed: Acute Heart Failure</description>
        <language>en</language>

        

                <item>
                    <title>SUMMIT: Benefits From Tirzepatide Similar By Sex in Patients With Obesity-Related HFpEF</title>
<link>/Latest-in-Cardiology/Journal-Scans/2026/07/16/18/06/summit</link>                    <description>Treatment benefit from tirzepatide was consistent across multiple domains of heart failure (HF) severity and did not differ by sex, despite women exhibiting greater adiposity, symptom severity and poorer exercise capacity but lower left ventricular mass and paracardiac fat deposition when compared to men, according to a secondary analysis of the SUMMIT trial published July 10 in JACC: Heart Failure.</description>
                    <pubdate>1784228460000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>Eagle&#39;s Eye View: The SHaRE Registry as a Predictor of MACE</title>
<link>/Latest-in-Cardiology/Articles/2026/07/15/14/19/eagles-eye-view-15jul2026</link>                    <description>In this week&#226;€™s View, Dr. Eagle looks at the feasibility of mechanical leaflet splitting in high-risk patients undergoing valve-in-valve transcatheter aortic valve replacement (TAVR).</description>
                    <pubdate>1784125200000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>SHaRe Registry Identifies MACE Predictors in Mild HCM</title>
<link>/Latest-in-Cardiology/Journal-Scans/2026/07/07/13/29/SHaRe-Registry</link>                    <description>About one in five patients with phenotypically mild hypertrophic cardiomyopathy (HCM) experienced major adverse cardiovascular events (MACE) over seven years of follow-up, according to SHaRe Registry research published July 8 in JACC.</description>
                    <pubdate>1783532640000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>Eagle&#226;€™s Eye View: Can Sugar-Sweetened Beverages and Fruit Juice Lead to Hypertension?</title>
<link>/Latest-in-Cardiology/Articles/2026/07/08/14/16/eagles-eye-view-08jul2026</link>                    <description>In this week&#226;€™s View, Dr. Eagle looks at withdrawing guideline-directed medical therapy (GDMT) for patients with atrial fibrillation (AF).</description>
                    <pubdate>1783520220000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>Eagle&#226;€™s Eye View: Clopidogrel vs. Aspirin Following PCI</title>
<link>/Latest-in-Cardiology/Articles/2026/07/01/12/47/eagles-eye-view-01jul2026</link>                    <description>In this week&#226;€™s View, Dr. Eagle looks at how genotype independently predicts heart failure outcomes in patients with hypertrophic cardiomyopathy (HCM).</description>
                    <pubdate>1782910140000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>Quality Improvement For Institutions | New Cardiogenic Shock Designation Addresses Deadly Gap in Chest Pain Care</title>
<link>/Latest-in-Cardiology/Articles/2026/07/01/01/Quality-Improvement-For-Institutions</link>                    <description>The ACC has announced a new Cardiogenic Shock Designation to improve outcomes for one of the most life-threatening complications of myocardial infarction. The new designation builds on the success of the ACC Chest Pain Center Accreditation, which has helped hospitals standardize and improve care...</description>
                    <pubdate>1782907980000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>Heart of Health Policy | ACC Urges Changes as Ambulatory Specialty Model Approaches</title>
<link>/Latest-in-Cardiology/Articles/2026/07/01/01/Heart-of-Health-Policy</link>                    <description>With the mandatory Ambulatory Specialty Model (ASM) for Heart Failure (HF) slated to begin Jan. 1, 2027, the ACC is prioritizing member awareness and education, while pressing the Centers for Medicare and Medicaid Services (CMS) to address key issues with the model&#39;s design and requirements.</description>
                    <pubdate>1782907860000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>JACC in a Flash | Consistent Renal Benefit With Semaglutide in T2D/CKD; Late Pericardial Effusion Post LAAO</title>
<link>/Latest-in-Cardiology/Articles/2026/07/01/01/JACC-in-a-Flash</link>                    <description>Featured topics and Editors&#39; Picks from all of ACC&#39;s JACC Journals.</description>
                    <pubdate>1782907800000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>Journal Wrap | PAD Screening Marker; Racial, Sex Disparities in M-TEER; More</title>
<link>/Latest-in-Cardiology/Articles/2026/07/01/01/Journal-Wrap</link>                    <description>The hottest research from various peer-reviewed journals &#226;€“ handpicked weekly by the ACC.</description>
                    <pubdate>1782907740000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>Do Patients With Reduced LVEF Undergoing LAAO Suffer Worse Outcomes?</title>
<link>/Latest-in-Cardiology/Journal-Scans/2026/06/29/15/38/Patients-With-Reduced-LVEF-Undergoing-LAAO</link>                    <description>There was no significant difference in procedural success, major in-hospital complications or stroke at one year in patients undergoing transcatheter left atrial appendage occlusion (LAAO) with reduced LVEF; however, these patients did exhibit higher mortality at one year...</description>
                    <pubdate>1782845400000</pubdate>
                    <category>Articles and Stories</category>
                </item>

    </channel>
</rss>